Posted by Michael Wonder on 06 Oct 2016
FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis
5 October 2016 - Fourteenth breakthrough therapy designation for Roche medicines.
Roche announced today that the U.S. FDA has granted breakthrough therapy designation status to Actemra/RoActemra (tocilizumab) for giant cell arteritis, a chronic, potentially life-threatening autoimmune condition.
The disease is caused by inflammation of large and medium-sized arteries, most often in the head, but also in the aorta and its branches.
